• FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage bufferPreservative: 0.05% Sodium azide
    Constituents: 99% PBS, 0.1% BSA
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Primary antibody notesThe second messengers cAMP and cGMP are key regulatory molecules that are involved in a wide variety of signal transduction pathways, such as insulin secretion, platelet aggregation, smooth muscle relaxation, olfaction, and vision. Levels of cAMP and cGMP are regulated by their rate of synthesis by nucleotide cyclases and by their rate of hydrolysis by cyclic nucleotide phosphodiesterases (PDEs). PDEs form a superfamily of enzymes that catalyze the conversion of 3-prime, 5-prime-cyclic nucleotides to the corresponding nucleoside 5-prime-monophosphates. While mammalian PDEs are divided into major families based on their substrate specificities, kinetic properties, allosteric regulators, inhibitor sensitivities, and amino acid sequences, each family and even members within a family display distinct tissue, cell, and subcellular expression patters. This suggests that individual PDE family members are involved in discrete signal transduction pathways. PDE6 is the effector enzyme in the G protein-mediated signal transduction cascade in the visual system. There are five different subunits consisting of rod and cone specific catalytic subunits: alpha’ (Cone), alpha (Rod), and beta (Rod), the inhibitory subunit gamma, and subunit delta of unknown function (which likely interacts with many other proteins besides the PDE6 family). The catalytic core of the PDE6 system is comprised of alpha’/alpha’ homodimers in the cone and alpha/beta heterodimers in the rod. The C-terminus of both the catalytic and inhibitory subunits is modified by methylation, myristyolation and prenylation which have been shown to be critical for proper complex assembly and membrane association.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas


Our Abpromise guarantee covers the use of ab5663 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
IP Use at an assay dependent concentration.
WB Use a concentration of 2 µg/ml. Detects a band of approximately 90 kDa.Can be blocked with PDE6 beta peptide (ab5890).
ICC/IF Use at an assay dependent concentration. PubMed: 17960120
IHC-Fr Use at an assay dependent concentration.


  • FunctionThis protein participates in processes of transmission and amplification of the visual signal. Necessary for the formation of a functional phosphodiesterase holoenzyme.
  • Involvement in diseaseDefects in PDE6B are the cause of retinitis pigmentosa type 40 (RP40) [MIM:613801]. RP40 is a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.
    Defects in PDE6B are a cause of congenital stationary night blindness autosomal dominant type 2 (CSNBAD2) [MIM:163500]; also known as congenital stationary night blindness Rambusch type. Congenital stationary night blindness is a non-progressive retinal disorder characterized by impaired night vision.
  • Sequence similaritiesBelongs to the cyclic nucleotide phosphodiesterase family.
    Contains 2 GAF domains.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • 5''-cyclic phosphodiesterase subunit beta antibody
    • Congenital stationary night blindness 3 autosomal dominant antibody
    • CSNB 3 antibody
    • CSNB3 antibody
    • CSNBAD2 antibody
    • GMP PDE beta antibody
    • GMP-PDE beta antibody
    • PDE 6 beta antibody
    • PDE 6B antibody
    • PDE6B antibody
    • PDE6B_HUMAN antibody
    • PDEB antibody
    • Phosphodiesterase 6B antibody
    • Phosphodiesterase 6B cGMP specific rod beta antibody
    • Rd 1 antibody
    • Rd1 antibody
    • Rod cGMP phosphodiesterase beta subunit antibody
    • Rod cGMP specific 3' 5' cyclic phosphodiesterase beta subunit antibody
    • Rod cGMP-specific 3'' antibody
    • RP40 antibody
    see all

Anti-PDE6 beta antibody images

  • Western blot of PDE6 beta using ab5663.
    Lane 1 demostrates no detection on extracts of RD mice.
    Lane 2 shows a single band at ~90 kDa on Balb/C extracts.

  • Immunofluorescences on frozen secions of mouse retina outer segments after staining with ab5663.

  • IHC image of ab5663 staining in mouse normal eye formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab5663, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

  • Immunofluorescence analysis of murine retinal stem cells, staining PDE6 beta (green) with ab5663 at 1/100 dilution.

References for Anti-PDE6 beta antibody (ab5663)

This product has been referenced in:
  • Sanges D  et al. Reprogramming Müller glia via in vivo cell fusion regenerates murine photoreceptors. J Clin Invest 126:3104-3116 (2016). WB ; Mouse . Read more (PubMed: 27427986) »
  • Emoto Y  et al. Green tea extract suppresses N-methyl-N-nitrosourea-induced photoreceptor apoptosis in Sprague-Dawley rats. Graefes Arch Clin Exp Ophthalmol 252:1377-84 (2014). Read more (PubMed: 25012920) »

See all 6 Publications for this product

Product Wall

Thank you for contacting us and sorry for the delay in getting back to you.

Unfortunately I can confirm that the have not tested the Anti-PDE6 beta antibody (ab5663) with Rat samples. The image which was on the datasheet was unfortunately mis...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Frozen sections)
Sample Mouse Tissue sections (Skin, Retina)
Specification Skin, Retina
Fixative Methanol
Permeabilization Yes - 0.4% TritonX-100
Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 10% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Nov 11 2011

Sorry for the delayed response. I have been unable to confirm the precise dilutions used in this image but would recommend starting at 1:100 and move to higher dilutions from there.